Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 11:40 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 1,743 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare Two Different Subcutaneously-administered JNJ-64304500 Formulations in Healthy Participants

NCT04667052
View directory record Official record
Conditions
Healthy
Interventions
JNJ 64304500
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
43 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Food on Nemtabrutinib (MK-1026) in Healthy Participants (MK-1026-017)

NCT06772818
View directory record Official record
Conditions
Healthy
Interventions
Nemtabrutinib
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Trial to Evaluate the Safety and Immunogenicity of Multivalent Pneumococcal Vaccines in Japanese Adults 18 to 49 Years of Age

NCT03642847
View directory record Official record
Conditions
Pneumococcal Infections
Interventions
Prevnar 13, multivalent pneumococcal conjugate formulation 1, multivalent pneumococcal conjugate formulation 2
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
4
States / cities
Garden Grove, California • Long Beach, California • Honolulu, Hawaii + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

Safety Study of Subcutaneously-Injected Prandial INSULIN-PH20 NP Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes Mellitus

NCT00883558
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Insulin Lispro, regular human insulin, recombinant human hyaluronidase PH20, Insulin glargine
Drug
Lead sponsor
Halozyme Therapeutics
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Aurora, Colorado • Miami, Florida • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

18611 - Sun Protection Factor Assay

NCT02760563
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY 987517
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study of Single and Multiple Doses of Rabeprazole in Pediatric Patients With Gastroesophageal Reflux Disease (GERD) 1 to 11 Months Old, Inclusive

NCT00747526
View directory record Official record
Conditions
Gastroesophageal Reflux Disease (GERD)
Interventions
Rabeprazole sodium 5 mg, Rabeprazole sodium 10 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
1 Month to 11 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
Little Rock, Arkansas • Oakland, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2013 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

Carboplatin and ABI-007 in Treating Patients With Stage IV Melanoma That Cannot Be Removed By Surgery

NCT00404235
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
carboplatin, paclitaxel albumin-stabilized nanoparticle formulation
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
156
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Aurora, Illinois + 98 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 3 Interventional

Efficacy and Safety APT-1011 in Adult Subjects With Eosinophilic Esophagitis (EoE) (FLUTE-2)

NCT04281108
View directory record Official record
Conditions
Eosinophilic Esophagitis
Interventions
APT-1011, Placebo oral tablet, Esophagogastroduodenoscopy
Drug · Procedure
Lead sponsor
Ellodi Pharmaceuticals, LP
Industry
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
48
States / cities
Anniston, Alabama • Dothan, Alabama • Mobile, Alabama + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2023 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Annual Study for Collection of Serum Samples in Children and Older Adults Receiving the 2021-2022 Formulations of Fluzone Quadrivalent Vaccine and Fluzone High-Dose Quadrivalent Vaccine, Respectively

NCT05050318
View directory record Official record
Conditions
Influenza Immunization, Healthy Volunteers
Interventions
Fluzone Quadrivalent vaccine, No Preservative (0.5-mL dose), 2021-2022 formulation, Fluzone High-Dose Quadrivalent vaccine (0.7-mL dose), 2021-2022 formulation
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Bardstown, Kentucky • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

Vardenafil Inhaled for Pulmonary Arterial Hypertension PRN Phase 2B Study

NCT04266197
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Combination Product
Lead sponsor
Respira Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study of the Fixed Dose Combination Tablets of Canagliflozin and Metformin Extended Release (XR) With Respect to the Individual Components in Healthy Fed Participants

NCT02071368
View directory record Official record
Conditions
Healthy
Interventions
Canagliflozin, 300 mg, Metformin XR, 500 mg, CANA/MET XR FDC, Formulation 1, 150 mg/500, CANA/MET XR FDC, Formulation 2, 150 mg/500 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Oct 29, 2026, 11:40 AM EDT
Active, not recruiting Phase 2 Interventional

A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)

NCT06946797
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Nivolumab, Ipilimumab, Carboplatin, Paclitaxel, Pemetrexed, Cisplatin
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Anchorage, Alaska • Los Angeles, California • Boise, Idaho + 3 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional

A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid Tumors

NCT00259935
View directory record Official record
Conditions
Lung Cancer, Small Cell
Interventions
topotecan
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
6
States / cities
Lebanon, New Hampshire • The Bronx, New York • Philadelphia, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

Safety & Immunogenicity of GlaxoSmithKline Biologicals' Herpes Zoster Vaccine 1437173A

NCT00920218
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
11
States / cities
Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Comparative Pharmacokinetic, Pharmacodynamic, and Safety Study of 1 Dose Level of Aspirin for Injection and Oral Aspirin Tablets in Healthy Adult Human Subjects

NCT05166096
View directory record Official record
Conditions
Healthy
Interventions
Rho-11, aspirin 325mg
Drug
Lead sponsor
Rhoshan Pharmaceuticals Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Relative Bioavailability and Food Effect of a New Tablet Formulation and Strength of Suzetrigine

NCT06336096
View directory record Official record
Conditions
Pain
Interventions
Suzetrigine
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)

NCT06099782
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Renal Cell Carcinoma, Melanoma
Interventions
Pembrolizumab (+) Berahyaluronidase alfa, Pembrolizumab
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
8
States / cities
Alexander City, Alabama • Anchorage, Alaska • Springdale, Arkansas + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 8, 2026 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway

NCT05194124
View directory record Official record
Conditions
Bardet-Biedl Syndrome, POMC Deficiency
Interventions
Setmelanotide 2 mg, Setmelanotide 2.5 mg, Setmelanotide 3 mg, Setmelanotide 20 mg, Setmelanotide 25 mg, Setmelanotide 30 mg
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
6 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Scottsdale, Arizona • Marshfield, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Bupropion Extended-Released 150 mg Tablets Under Fasting Conditions

NCT00865410
View directory record Official record
Conditions
Healthy
Interventions
Abrika Bupropion 150 mg Extended-Released Tablet, Wellbutrin SR® 150 mg Extended-Release Tablet, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years to 45 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fort Myers, Florida
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 2 Interventional Results available

Study in Advanced Parkinson's Disease Patients With Predictable Motor Fluctuations

NCT01515410
View directory record Official record
Conditions
Parkinson's Disease, Motor Fluctuations
Interventions
DM-1992, Sinemet IR
Drug
Lead sponsor
Depomed
Industry
Eligibility
30 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
7
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Long Beach, California + 4 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 29, 2026, 11:40 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluation of Adhesion Quality of a New Formulation of the Mylan Estradiol Transdermal System 0.025 mg/Day and Climara® Transdermal System 0.025 mg/Day

NCT00649896
View directory record Official record
Conditions
Healthy
Interventions
Mylan Estradiol Transdermal System 0.025 mg/day, Climara® Transdermal System 0.025 mg/day
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
40 Years to 69 Years · Female only
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 1, 2008 · Synced Oct 29, 2026, 11:40 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Study of Ixekizumab in Healthy Participants

NCT03848403
View directory record Official record
Conditions
Healthy
Interventions
Ixekizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 30, 2022 · Synced Oct 29, 2026, 11:40 AM EDT